Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alogliptin - Takeda

Drug Profile

Alogliptin - Takeda

Alternative Names: Alogliptin benzoate; NESINA; Nesina; SYR-322; TAK-322; Vipidia

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Syrrx Inc
  • Developer Takeda
  • Class Antihyperglycaemics; Benzonitrile; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 14 Feb 2022 Takeda completes a phase III trial for Type-2 diabetes mellitus (In adolescents, In children, Monotherapy, Adjunctive treatment) in Brazil, Germany, Israel, Italy, Mexico, Poland and US (PO, Tablet) (NCT02856113)
  • 16 Apr 2021 Phase-III development in Type-2 diabetes mellitus (In adolescents, In children, Monotherapy, Adjunctive treatment) is ongoing in USA (PO) (NCT02856113)
  • 16 Apr 2021 Discontinued - Preregistration for Type 2 diabetes mellitus in Indonesia (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top